Erasca, Inc. (ERAS)
13.27
-0.10
(-0.75%)
USD |
NASDAQ |
Jun 11, 10:55
Erasca Enterprise Value : 3.958B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 3.958B |
| June 09, 2026 | 3.970B |
| June 08, 2026 | 3.802B |
| June 05, 2026 | 3.523B |
| June 04, 2026 | 3.927B |
| June 03, 2026 | 3.899B |
| June 02, 2026 | 3.992B |
| June 01, 2026 | 4.098B |
| May 29, 2026 | 3.793B |
| May 28, 2026 | 3.594B |
| May 27, 2026 | 3.680B |
| May 26, 2026 | 3.378B |
| May 22, 2026 | 3.298B |
| May 21, 2026 | 3.411B |
| May 20, 2026 | 3.260B |
| May 19, 2026 | 3.012B |
| May 18, 2026 | 2.996B |
| May 15, 2026 | 2.984B |
| May 14, 2026 | 3.027B |
| May 13, 2026 | 3.055B |
| May 12, 2026 | 3.030B |
| May 11, 2026 | 3.049B |
| May 08, 2026 | 2.949B |
| May 07, 2026 | 3.036B |
| May 06, 2026 | 3.192B |
| Date | Value |
|---|---|
| May 05, 2026 | 2.909B |
| May 04, 2026 | 2.955B |
| May 01, 2026 | 2.921B |
| April 30, 2026 | 3.114B |
| April 29, 2026 | 2.635B |
| April 28, 2026 | 2.881B |
| April 27, 2026 | 5.757B |
| April 24, 2026 | 6.484B |
| April 23, 2026 | 6.789B |
| April 22, 2026 | 6.534B |
| April 21, 2026 | 6.770B |
| April 20, 2026 | 6.552B |
| April 17, 2026 | 5.713B |
| April 16, 2026 | 5.470B |
| April 15, 2026 | 5.461B |
| April 14, 2026 | 5.350B |
| April 13, 2026 | 4.871B |
| April 10, 2026 | 5.089B |
| April 09, 2026 | 5.198B |
| April 08, 2026 | 5.067B |
| April 07, 2026 | 5.105B |
| April 06, 2026 | 5.123B |
| April 02, 2026 | 5.338B |
| April 01, 2026 | 4.962B |
| March 31, 2026 | 4.831B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Revolution Medicines, Inc. | 27.39B |
| Tango Therapeutics, Inc. | 3.788B |
| Kymera Therapeutics, Inc. | 5.859B |
| Bridgebio Oncology Therapeutics, Inc. | 320.60M |
| ImmunityBio, Inc. | 8.055B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -183.44M |
| Total Expenses (Quarterly) | 183.44M |
| EPS Diluted (Quarterly) | -0.6028 |
| Earnings Yield | -7.03% |
| Normalized Earnings Yield | -4.252 |